FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Flags SK Life Sciences Xcopri TV Ad as Misleading

[ Price : $8.95]

FDA issues an untitled letter to SK Life Science, raising concerns over a direct-to-consumer television advertisement for its seiz...

Woodcock Urges Stronger FDA Role in Updating Generic Labels

[ Price : $8.95]

Former FDA principal deputy commissioner Janet Woodcock and policy experts from Duke University call on the agency to adopt new to...

FDA Probes Death Associated With Takedas Adzynma

[ Price : $8.95]

FDA investigates the death of a pediatric patient with congenital thrombotic thrombocytopenic purpura who developed neutralizing a...

Sterility Failures Flagged at Indian Injectable Drug Maker

[ Price : $8.95]

FDA investigators cite Immacule Lifesciences Private Limited, a sterile drug contract manufacturer in Himachal Pradesh, India, for...

White House Sought Resignation of Top Makary Aide

[ Price : $8.95]

New reporting finds that the White House recently requested the resignation of a senior aide to FDA commissioner Marty Makary, hig...

Intersurgical Recalls Video Laryngoscope Due to Safety

[ Price : $8.95]

Intersurgical recalls (Class 1) its i-View Video Laryngoscope, citing serious safety risks that could potentially lead to severe i...

Makary, RFK, Jr., Feuding Over Vaccines: Politico

[ Price : $8.95]

Politico reports that FDA commissioner Marty Makary and HHS secretary Robert F. Kennedy, Jr., are feuding over vaccine safety stud...

Medline Convenience Kit Recall is Class 1

[ Price : $8.95]

FDA says the Medline 8/22 recall of three models of surgical convenience kits that were not sterilized is Class 1.

FDA OKs Regenerons High-Dose Eylea

[ Price : $8.95]

FDA approves Regeneron Pharmaceuticals Eylea HD (aflibercept 8 mg) for treating macular edema following retinal vein occlusion.

Nuvalent NDA for ROS1 Inhibitor in Lung Cancer

[ Price : $8.95]

FDA accepts for review a Nuvalent NDA for zidesamtinib, a next-generation ROS1-selective tyrosine kinase inhibitor being developed...